Recurrent Malignant Glioma Global Clinical Trials Review, H2, 2016

GlobalData
148 Pages - GLDATA58519
$2,500.00

Summary

GlobalData's clinical trial report, “Recurrent Malignant Glioma Global Clinical Trials Review, H2, 2016" provides an overview of Recurrent Malignant Glioma clinical trials scenario. This report provides top line data relating to the clinical trials on Recurrent Malignant Glioma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Companies Mentioned

F. Hoffmann-La Roche Ltd.
Merck & Co., Inc.
AstraZeneca Plc
INSYS Therapeutics, Inc.
Eisai Co., Ltd.
Novartis AG
Eli Lilly and Company
Sanofi
Pfizer Inc.
Aeterna Zentaris Inc.

'

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Recurrent Malignant Glioma to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Recurrent Malignant Glioma to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Recurrent Malignant Glioma Therapeutics Clinical Trials 28
Prominent Drugs 30
Clinical Trial Profile Snapshots 31
Appendix 145
Abbreviations 145
Definitions 145
Research Methodology 146
Secondary Research 146
About GlobalData 147
Contact Us 147
Disclaimer 147
Source 148

List of Tables
Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials by Region, 2016* 6
Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8
Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
Recurrent Malignant Glioma Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2016* 10
Recurrent Malignant Glioma Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11
Recurrent Malignant Glioma Therapeutics Clinical Trials, North America, Top Countries, 2016* 12
Recurrent Malignant Glioma Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 13
Recurrent Malignant Glioma Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 14
Proportion of Recurrent Malignant Glioma to Oncology Clinical Trials, G7 Countries (%), 2016* 15
Recurrent Malignant Glioma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16
Recurrent Malignant Glioma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17
Proportion of Recurrent Malignant Glioma to Oncology Clinical Trials, E7 Countries (%), 2016* 18
Recurrent Malignant Glioma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19
Recurrent Malignant Glioma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20
Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials by Phase, 2016* 21
Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 22
Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23
Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24
Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25
Recurrent Malignant Glioma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 26
Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27
Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 29
Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 30

List of Figures
Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
Recurrent Malignant Glioma Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2016* 10
Recurrent Malignant Glioma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11
Recurrent Malignant Glioma Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12
Proportion of Recurrent Malignant Glioma to Oncology Clinical Trials, G7 Countries (%), 2016* 15
Recurrent Malignant Glioma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16
Recurrent Malignant Glioma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17
Proportion of Recurrent Malignant Glioma to Oncology Clinical Trials, E7 Countries (%), 2016* 18
Recurrent Malignant Glioma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19
Recurrent Malignant Glioma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20
Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials by Phase (%), 2016* 21
Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 22
Recurrent Malignant Glioma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23
Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24
Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25
Recurrent Malignant Glioma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 26
Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27
Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
Recurrent Malignant Glioma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 30
GlobalData Methodology 146

$2,500.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838



Browse All Reports